In the 12 months to Nov 19, 2026, on the open market: bought $1.2M of KRRO, PASG. Filed a median of 2 business days after the trade.
Open-market purchases and sales this filer reported on SEC Form 4, by the day traded. Insiders have two business days to file. A sale marked 10b5-1 was made under a plan adopted in advance. How to read these
Insider purchases above the line: $1.2MInsider sales below: $0
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.
KRROBought: Korro Bio, Inc. Oct 26, 202625,124 sharesfiled Oct 26, 20261,624,789 shares held indirectly after, as filedfiling$295K
KRROBought: Korro Bio, Inc. Oct 23, 20262,510 sharesfiled Oct 26, 20261,599,665 shares held indirectly after, as filedfiling$30K
KRROBought: Korro Bio, Inc. Oct 22, 202652,175 sharesfiled Oct 26, 20262 transactionsfiling$559K
KRROBought: Korro Bio, Inc. Aug 10, 20261,462 sharesfiled Aug 13, 20261,544,980 shares held indirectly after, as filedfiling$19K
KRROBought: Korro Bio, Inc. Aug 6, 20265,222 sharesfiled Aug 13, 20261,543,518 shares held indirectly after, as filedfiling$60K
PASGBought: Passage BIO, Inc. Jun 25, 202650,055 sharesfiled Jun 29, 2026673,759 shares held indirectly after, as filedfiling$206K
Source: SEC Form 4 filings. Value is shares × the price reported on the filing; a filing whose price failed Lytir's check against the market price is left out, and a trade that related owners reported on separate forms is counted once. Filings can be late, amended or wrong at the source; see methodology.
Stakes filed (13D/13G)
Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Filings made under this filer's SEC CIK in the same 12 months, newest first; the figure is the percentage the filing states. Every recent 13D and 13G
GHRSLynx1 Capital Management LP filed Aug 14, 2026Schedule 13G/Apassiveissuer: GH Research PLCfiling19.3%
TCRXLynx1 Capital Management LP filed Aug 14, 2026Schedule 13G/Apassiveissuer: TScan Therapeutics, Inc.filing13.1%
CCCCLynx1 Capital Management LP filed Aug 14, 2026Schedule 13G/Apassiveissuer: C4 Therapeutics, Inc.filing9.99%
STOKLynx1 Capital Management LP filed Aug 14, 2026Schedule 13G/Apassiveissuer: Stoke Therapeutics, Inc.filing6.5%
IBIOLynx1 Capital Management LP filed Aug 14, 2026Schedule 13Gpassiveissuer: iBio, Inc.filing5.4%